Maria Soloveychik is the co-founder and CEO of SyntheX, a therapeutics company accelerating drug discovery through synthetic biology. SyntheX, founded in 2016 and headquartered in San Francisco, advances its own oncology pipeline and partners in external discovery collaborations. Maria holds a PhD in Molecular Genetics from the University of Toronto, where her research uncovered novel pathways linking metabolism and epigenetic signaling. As a former research scientist at the Structural Genomics Consortium, her work contributed to determining numerous protein structures and identifying several promising drug candidates.